Age
|
Median age, years (range)
|
52.5 (18–78)
|
< 65
|
87 (85.3)
|
≥ 65
|
15 (14.7)
|
Gender
|
Male
|
70 (68.6)
|
Female
|
32 (31.4)
|
ECOG PS
|
0
|
19 (18.6)
|
1
|
83 (81.4)
|
Prior lines of systemic therapy
|
1
|
42 (41.2)
|
2
|
34 (33.3)
|
3 or above
|
26 (25.5)
|
Stage of disease#
|
I–II
|
17 (16.7)
|
III–IV
|
84 (82.4)
|
Pathological subtype$
|
PTCL-NOS
|
41 (40.2)
|
ENKTL
|
23 (22.5)
|
ALCL ALK-
|
12 (11.8)
|
ALCL ALK+
|
7 (6.9)
|
Other subtypes*
|
19(18.6)
|
Prior therapies
|
Multi-agent regimen
|
For ENKTL
|
Asparaginase-based chemotherapy†
|
21 (91.3)
|
For other subtypes of PTCL
|
Anthracycline-containing chemotherapy‡
|
77 (97.5)
|
Single-agent regimen
|
Chidamide
|
24 (23.5)
|
Gemcitabine
|
55 (53.9)
|
Methotrexate
|
10 (9.8)
|
Bortezomib
|
1 (1.0)
|
Radiotherapy
|
32 (31.4)
|
Autologous stem-cell transplantation
|
7 (6.9)
|